Table 1.
Characteristics of 3,331 Men at 20-Year Follow-up According to Physical Activity Trajectory Group, British Regional Heart Study, 1978–2000
| Physical Activity Trajectory Group | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Low/Decreasing (n = 708) | Light/Stable (n = 1,725) | Moderate/Increasing (n = 898) | Total (n = 3,331) | ||||||||||||
| No. | % | Mean (SD) | Median (IQR) | No. | % | Mean (SD) | Median (IQR) | No. | % | Mean (SD) | Median (IQR) | No. | % | Mean (SD) | Median (IQR) | |
| Age | 69.4 (5.7) | 68.5 (5.5) | 67.7 (5.1) | 68.5 (5.5) | ||||||||||||
| Manual occupational class | 428 | 60.5 | 966 | 56.0 | 350 | 39.0 | 1,744 | 52.4 | ||||||||
| Current/recent former-smoker | 276 | 39.0 | 395 | 22.9 | 158 | 17.6 | 829 | 24.9 | ||||||||
| At least moderate alcohol consumptiona | 129 | 18.2 | 340 | 19.7 | 172 | 19.2 | 641 | 19.2 | ||||||||
| Resident in southern England | 189 | 26.7 | 608 | 35.3 | 339 | 37.8 | 1,136 | 34.1 | ||||||||
| Taking antihypertensive medication | 298 | 42.1 | 520 | 30.1 | 215 | 23.9 | 1,033 | 31.0 | ||||||||
| Taking lipid-lowering medication | 54 | 7.6 | 113 | 6.6 | 63 | 7.0 | 230 | 6.9 | ||||||||
| Taking warfarin | 26 | 3.7 | 50 | 2.9 | 18 | 2.0 | 94 | 2.8 | ||||||||
| HDL, mmol/L | 1.3 (0.3) | 1.3 (0.3) | 1.4 (0.3) | 1.3 (0.3) | ||||||||||||
| LDL, mmol/L | 3.8 (1.0) | 4.0 (1.0) | 3.9 (0.9) | 3.9 (1.0) | ||||||||||||
| Total cholesterol, mmol/L | 5.9 (1.0) | 6.0 (1.1) | 6.0 (1.1) | 6.0 (1.1) | ||||||||||||
| Triglycerides, mmol/L | 1.7 (1.2) | 1.6 (1.0) | 1.5 (1.0) | 1.6 (1.0) | ||||||||||||
| Glucose, mmol/L | 1.7 (0.2) | 1.7 (0.1) | 1.7 (0.1) | 1.7 (0.2) | ||||||||||||
| Insulin, μ/mL | 9.6 (8.0) | 8.1 (6.0) | 7.5 (5.3) | 8.2 (6.4) | ||||||||||||
| HbA1C, mmol/L | 5.0 (0.8) | 4.8 (0.7) | 4.8 (0.7) | 4.8 (0.8) | ||||||||||||
| Hypertensionb | 424 | 59.9 | 865 | 50.1 | 401 | 44.7 | 1,690 | 50.7 | ||||||||
| FEV1, Lc | 234.5 (67.4) | 260.2 (63.4) | 276.5 (61.1) | 259.1 (65.3) | ||||||||||||
| Waist circumference, cm | 99.9 (10.9) | 96.5 (10.0) | 95.3 (9.5) | 96.9 (10.2) | ||||||||||||
| IL-6, pg/mL | 2.8 (2.5) | 2.2 (1.8) | 2.0 (1.5) | 2.2 (1.9) | ||||||||||||
| Factor VIII, IU/dL | 138.2 (31.6) | 130.8 (31.0) | 127.5 (29.5) | 131.5 (31.0) | ||||||||||||
| von Willebrand factor, IU/dL | 147.9 (48.0) | 137.5 (44.5) | 133.4 (43.6) | 138.6 (45.3) | ||||||||||||
| tPA antigen, ng/mL | 12.3 (4.9) | 10.8 (4.2) | 10.2 (4.0) | 11.0 (4.4) | ||||||||||||
| CRP, mg/L | 2.3 (4.0) | 1.4 (2.4) | 1.2 (1.9) | 1.5 (2.6) | ||||||||||||
| D-dimer, ng/mL | 86.0 (106.0) | 75.0 (75.0) | 68.0 (60.0) | 74 (77.0) | ||||||||||||
| Hs-TnT, pg/mL | 12.6 (8.2) | 11.3 (7.0) | 11.5 (6.3) | 11.6 (7.1) | ||||||||||||
| NT-proBNP, pg/mLd | 108.0 (208.0) | 87.0 (133.0) | 76.5 (108.0) | 88.0 (141.0) | ||||||||||||
Abbreviations: CRP, c-reactive protein; FEV1, forced expiratory volume in 1 second; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; Hs-TnT, high-sensitivity cardiac troponin T; IL-6, interleukin-6; IQR, interquartile range; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic peptide; SD, standard deviation; tPA, tissue plasminogen activator.
a Moderate alcohol consumption was defined as 16–42 drinks/week.
b Hypertension was defined as a systolic blood pressure of ≥160 mm Hg, diastolic blood pressure ≥100 mm Hg, or use of antihypertensive medication.
c Standardized for height by multiplying FEV1 by the square of the mean population height (meters) divided by each participant’s height.
d Data were missing for an additional 194 men (n = 3,137).